Working… Menu

Prevalence of Clopidogrel (Plavix) Resistance in Hemodialysis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01865890
Recruitment Status : Completed
First Posted : May 31, 2013
Last Update Posted : May 31, 2013
Staten Island University Hospital
Information provided by (Responsible Party):
Suzanne El-Sayegh, Northwell Health

Brief Summary:
The investigators are trying to find out if Clopidogrel (Plavix) is as effective in hemodialysis patients as in patients not hemodialysed.

Condition or disease
Cardiovascular Disease

Detailed Description:

Cardiovascular disease is very frequent in hemodialysis patients. Lot of hemodialysis patients are on Clopidogrel (plavix). Their is some evidence that clopidogrel is not effective in hemodialysis as it is effective in patient without kidney problem.

VerifyNow plavix is a machine that measure the ability of the blood to clot after giving plavix.

We will collect blood from hemodialysis patients on plavix and check the ability of their blood to clot and thus indirectly measuring the efficacy of Plavix.

Layout table for study information
Study Type : Observational
Actual Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prevalence of Clopidogrel (Plavix) Resistance in Hemodialysis Patients
Study Start Date : June 2010
Actual Primary Completion Date : April 2011
Actual Study Completion Date : April 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dialysis

patient on hemodialysis taking plavix
patient on hemodialysis taking plavix

Primary Outcome Measures :
  1. Prevalence Of Plavix resistance [ Time Frame: 1 day ( one study visit) ]
    Plavix resistance is reported using the PRU values given by the VerifyNow machine. PRU is P2Y12 Reaction Units which is correlated with platelet aggregation.

Secondary Outcome Measures :
  1. assess the risk factors for plavix resistance in the hemodialysis population [ Time Frame: 1 day (one study visit) ]
    Coronary Artery Disease (CAD) is very common in dialysis patients. Treatment of CAD include medical therapy, stent placement and surgery. Since Plavix is a medication that is commonly used after stent placement, we would like to assess the efficacy of this medication in this patient population.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Hemodialysis patients who are taking plavix daily

Inclusion Criteria:

  • All patients on hemodialysis taking Plavix

Exclusion Criteria:

  • known to have bleeding disorder
  • Severely anemic with hemoglobin level (Hb) < 10g/dl
  • Low Platelets < 10000

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01865890

Layout table for location information
United States, New York
Staten Island University Hospital
Staten Island, New York, United States, 10305
Sponsors and Collaborators
Northwell Health
Staten Island University Hospital
Layout table for investigator information
Principal Investigator: Suzanne El-Sayegh, MD Staten Island University Hospital

Layout table for additonal information
Responsible Party: Suzanne El-Sayegh, Nephrology Attending, Assoc. Chair of Medicine, Northwell Health Identifier: NCT01865890     History of Changes
Other Study ID Numbers: 10-016
First Posted: May 31, 2013    Key Record Dates
Last Update Posted: May 31, 2013
Last Verified: May 2013
Keywords provided by Suzanne El-Sayegh, Northwell Health:
Plavix or clopidogrel resistance
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs